Updated

Updated · ScienceDaily · Jul 3

Weizmann Scientists Find MTCH2 Switch Boosts Fat Burning, Blocking New Fat Cells in Human Studies

Updated

Updated · ScienceDaily · Jul 3

Weizmann Scientists Find MTCH2 Switch Boosts Fat Burning, Blocking New Fat Cells in Human Studies

Q: Since its discovery last year, how close are we to a human trial for this new obesity treatment?

We are still far from a human trial. The MTCH2, or “Mitch,” work published in 2025 is still basic-stage research. The results come from experiments in human cells in the lab and from earlier mouse studies, not from testing a drug or treatment in people. The reporting around the study explicitly says it is “still far from becoming a treatment.” That matters because the finding is a biological target, not a therapy ready for the clinic. Researchers have shown that disabling Mitch can increase fat burning, raise energy use and block new fat-cell formation, but they have not yet shown how to do this safely in a living human body. MTCH2 is also involved in core mitochondrial functions and apoptosis-related pathways, so any drug aimed at it would need careful safety testing to avoid harmful effects on healthy tissues. Before any human trial, scientists would typically need to develop a practical way to target Mitch, test it in animals for efficacy and toxicity, work out dosing, and show that it does not cause unacceptable side effects such as damage to muscle, liver or other organs. So the discovery is promising, but it is still at the target-identification stage rather than the clinical-development stage. There is no indication in the available reporting that a human trial has been scheduled or is close.

2 articles · Updated · ScienceDaily · Jul 3

Human-cell experiments showed that deleting MTCH2, or “Mitch,” increased fat and carbohydrate burning while making it harder for progenitor cells to mature into new fat-storing cells.
More than 100 metabolic substances were tracked after the protein was removed, and researchers found fragmented mitochondria left cells in a chronic energy shortfall that drove higher respiration and heavier reliance on fat as fuel.
Mouse work had already linked missing Mitch to leaner bodies, greater endurance, more muscle fibers and better heart function, helping explain why the team tested the mechanism in human cells.
The EMBO Journal study points to a possible obesity-treatment pathway that could raise energy expenditure and limit fat storage, though the findings remain at the cell-study stage rather than a therapy.

Sources

ScienceDaily11h ago

Weizmann Institute Scientists Discover Protein 'Mitch' Regulates Fat Burning, Blocks New Fat Cells

unityphysio.com7h ago

This Newly Discovered Protein Could Solve Obesity Treatment's Biggest Problem — Losing Muscle Along With Fat - Unity Physio

How can disabling the 'Mitch' protein both burn fat and cause fat droplets to accumulate in cells?

Since its discovery last year, how close are we to a human trial for this new obesity treatment?

What are the long-term risks of a weight loss drug that also meddles with programmed cell death?

MTCH2’s Dual Mechanism: Revolutionizing Fat Loss and Obesity Therapy by Burning Fat and Preventing New Fat Cells

Overview

A major study led by Professor Atan Gross has revealed that the protein MTCH2, also called 'Mitch,' plays a powerful dual role in fighting body fat. MTCH2 not only speeds up fat burning by increasing the number of mitochondria in fat cells, making them better at turning fat into energy, but also stops new fat cells from forming by blocking immature cells from maturing into fat-storing cells. These effects were seen in both human cell and animal studies, showing that MTCH2 could be a promising target for new obesity treatments that both reduce existing fat and prevent future fat gain.

...